NCT04553666

Reducing Frailty for Older Cancer Survivors Using Supplements

Reducing Frailty for Older Cancer Survivors Using Supplements (ReFOCUS): A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University of Rochester · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer

Conditions

• Frailty
• Inflammation

Interventions

Type	Name	Description
DRUG	Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)	800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks

Timeline

• Start date: 2021-04-28
• Primary completion: 2023-08-31
• Completion: 2023-08-31
• First posted: 2020-09-17
• Last updated: 2024-09-19
• Results posted: 2024-09-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study